Introduction: Early postoperative mobilization and rehabilitation with minimal pain and discomfort is the most desirable feature in modern orthopaedic surgeries.The striking feature ofDexmedetomidine is the absence of opioid related side effects like respiratory depression, pruritis, nausea and vomiting.We studied the analgesic and sedative effects of dexmedetomidine when used epidurally in low concentration (0.5µg/kg) as an adjuvant to 0.5% isobaric bupivacaine in patients undergoing elective lower limb surgeries.Methods: This was a prospective randomized study carried out over a period of 18 months involving 60 patients aged 20-55 years of ASA grade I & II scheduled for elective lower limb surgeries. Group D patients were administered 18 ml of 0.5% isobaric bupivacaine with 0.5 µg/kg dexmedetomidine. Group P patients were administered 18 ml of 0.5% isobaric bupivacaine with normal saline, volume made equivalent to that of dexmedetomidine.Results: Both groups were comparable with regards to age, weight, height distribution, and ASA grading. Duration of sensory and motor blockade: The patients in Group D had a faster onset, better sedation, prolonged time for twosegment regression, and longer duration of sensory and motor blockade. The incidence of side effects such as hypotension and bradycardia was comparable in both groups.Conclusion: Low dose (0.5μg/kg) epidural dexmedetomidine is an effective adjuvant to epidural bupivacaine for prolonged surgeries, with minimal side effects and excellent postoperative analgesia.